Cellectar Biosciences (CLRB)
(Real Time Quote from BATS)
$2.95 USD
-0.16 (-5.15%)
Updated May 28, 2024 03:24 PM ET
2-Buy of 5 2
D Value C Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CLRB 2.95 -0.16(-5.15%)
Will CLRB be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for CLRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CLRB
Is Cellectar Biosciences (CLRB) Outperforming Other Medical Stocks This Year?
CLRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CLRB
Cellectar Biosciences files for $300M mixed securities shelf
Cellectar Biosciences files $300M mixed securities shelf
Eli Lilly inks radiopharma deal worth up to $1.1B with Aktis
Cellectar Biosciences: Still Working On That Hit (Maintain Buy)
Buy Rating on Cellectar Biosciences Backed by Strong Clinical Data and Promising Drug Pipeline